Objective Create a timeline of diagnosis and treatment for IPF in the US. Design, setting, and
participants A retrospective analysis was performed in collaboration with the OptumLabs …

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown
cause. Approximately 5,000 people are diagnosed with IPF in the UK every year. People …

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …

The long-standing need to determine an effective medical treatment regimen with clinically
significant and relevant end-points to improve outcome for patients with idiopathic …

Patients with idiopathic pulmonary fibrosis (IPF) inevitably experience declines in functional
status that are most frequently due to progressive pulmonary fibrosis. However, the cause of …

Idiopathic pulmonary fibrosis (IPF) is a devastating progressive disease associated with a
high mortality rate. Novel antifibrotic therapies have been recently demonstrated to slow …

Introduction Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease for which
two effective antifibrotics, nintedanib and pirfenidone, are available. However, many patients …

Introduction Recent developments in the care of patients with idiopathic pulmonary fibrosis
have the potential to improve survival rates. Population-based estimates of the current …

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has
been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND …

Rationale: Mortality prediction is well studied in idiopathic pulmonary fibrosis (IPF), but little
is known about predictors of premortality disease progression. Identification of patients at …